Feature | Stents Bioresorbable | October 16, 2015

Absorb Bioresorbable Scaffold Non-Inferior Xience Stent in ABSORB III Trial

U.S. FDA regulatory approval trial shows bioresorbable stent performs as well as market leading metalic drug-eluting stent

ABSORB III trial, TCT 2015, bioresorbable vascular scaffold, BVS

Abbott's Absorb bioresorbable stent. Image courtesy of Abbott Vascular

October 16, 2015 — Results from a clinical trial showed that Abbott's Absorb everolimus-eluting bioresorbable vascular scaffold was non-inferior after one year compared to Abbott's Xience V, the best current generation metallic drug-eluting stent (DES) on the market. The trial compared the two stents in patients with coronary artery disease and measured target lesion failure (TLF) was the primary endpoint. Findings from the ABSORB III trial were presented at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The study was also published in the New England Journal of Medicine.

As the largest and pivotal clinical trial designed for regulatory approval, data from the ABSORB III trial will be reviewed by the U.S. Food and Drug Administration (FDA) as it considers whether or not to approve this device. With the positive trial results, it is possible the FDA may consider approval of the stent for the U.S. market in the coming months. If approved, it would be the first fully bioresorbable vascular scaffold (BVS) on the U.S. market. 

BVS have been developed to provide mechanical support and drug delivery functions similar to DES for approximately one year, followed by complete absorption back into the body over about three years, potentially improving long-term clinical outcomes. However, whether BVS are as safe and effective as DES within the first year had not yet been established.

 

Trial Results

As a prospective, multicenter, single-blind, active-treatment controlled clinical trial, ABSORB III measured the safety and efficacy of BVS compared to DES at one year in patients with obstructive coronary artery disease. The trial randomized 2,008 patients with myocardial ischemia undergoing treatment of one or two de novo native coronary artery lesions from 193 clinical sites. Patients were randomized 2:1 to receive an everolimus-eluting BVS (n=1,322) or a cobalt-chromium everolimus-eluting stent (CoCr-EES; n=686). The primary endpoint was target lesion failure (cardiac death, target-vessel myocardial infarction or ischemia-driven target lesion revascularization) at one year. Key findings included:

• A primary endpoint of target lesion failure (TLF) of 7.8 percent for Absorb and 6.1 percent for Xience (non-inferiority p<0.007, no statistically significant difference), demonstrating that both devices are comparable in treating people with CAD. TLF is a composite of heart disease-related deaths, heart attacks attributed to the treated vessel, and repeat procedures within the treated lesion caused by ischemia (lack of oxygen in the treated vessel).

• All pre-specified secondary endpoint results were not statistically different.

• There was no statistically significant difference in the rate of definite and/or probable stent thrombosis (ST).

Patients treated with BVS and CoCr-EES had non-significantly different rates of cardiac death (0.6 vs. 0.1 percent, P=0.29), target-vessel myocardial infarction (6 vs. 4.6 percent, P=0.18), and stent thrombosis (1.5 vs. 0.7 percent, P=0.13). In addition, there were no statistically significant differences between BVS and CoCr-EES in the one-year rates of ischemia-driven target lesion revascularization (3 vs. 2.5 percent, P=0.50), angina (18.3 vs. 18.4 percent, P=0.93) or ischemia-driven TVR (5 vs. 3.7 percent, P=0.21).

“Bioresorbable vascular scaffolds are the newest generation of stent technology aimed at improving long-term outcomes in patients,” said lead investigator Dean J. Kereiakes, M.D., medical director of The Christ Hospital Heart and Vascular Center and the Lindner Research Center in Cincinnati, Ohio. “Results from the ABSORB III trial showed that treatment of non-complex obstructive coronary artery disease with BVS was non-inferior to the best in class CoCr-EES for target lesion failure at one year. Long-term follow-up data from this and other large-scale trials are required to determine whether these findings translate into improved longer-term clinical outcomes beyond one year.”

Gregg W. Stone, M.D., study chairman of the ABSORB III trial noted, “This device may be an attractive alternative for young patients, for those with acute coronary syndromes in whom metallic stents heal poorly, and for patients and physicians wishing to avoid a permanent implant. The real potential advantages, however, are expected to emerge over time as the device dissolves, restoring the normal functioning of the coronary artery.” Stone is co-director of the Cardiovascular Research Foundation’s Medical Research and Education Division. He is also professor of medicine at Columbia University College of Physicians and Surgeons and director of cardiovascular research and education at the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia University Medical Center.

 

Other Key Absorb Data at TCT 2015

At this year's TCT, Abbott also presented positive one-year results from ABSORB China, a prospective, randomized, single-blinded, controlled trial that compared Absorb to Xience to support Absorb approval in China. The trial met its non-inferiority primary endpoint of in-segment late loss at one year, with Absorb at 0.19±0.38 mm and Xience at 0.13 ±0.38 mm (P non-inferiority=0.01). The trial enrolled 480 people at 24 sites throughout mainland China. The results were published simultaneously in the Journal of the American College of Cardiology. During TCT Abbott will present additional data from the Absorb family of trials, which have collectively involved more than 13,000 people.

The ABSORB III trial was funded by Abbott Vascular. Kereiakes reports consulting fees from HCRI, Boston Scientific, Abbott Vascular, Svelte Medical Systems Inc., Janssen Research & Development LLC,

Sanofi-Aventis U.S. LLC, and major stock shareholder/equity in Ablative Solutions Inc. Stone reports receiving personal fees from Osprey, Boston Scientific, InspireMD, TherOx, Atrium, Miracor, Eli Lilly-Daiichi Sankyo partnership, AstraZeneca and Velomedix.

For more information: www.tctconference.com

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init